All in on ide-cel, Bristol Myers Squibb writes off $470M as second BCMA CAR-T is ejected from the pipeline
With just a little over a month to go before the FDA is slated to decide on ide-cel, Bristol Myers Squibb is writing off $470 million as it scraps a second BCMA CAR-T, dubbed orva-cel.
While ide-cel was the subject of a Celgene collaboration with bluebird bio, orva-cel was originally developed by Juno Therapeutics, which Celgene snapped up for $9 billion before getting acquired by Bristol Myers Squibb itself.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.